WO2003040308A3 - Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo - Google Patents

Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo Download PDF

Info

Publication number
WO2003040308A3
WO2003040308A3 PCT/US2002/024235 US0224235W WO03040308A3 WO 2003040308 A3 WO2003040308 A3 WO 2003040308A3 US 0224235 W US0224235 W US 0224235W WO 03040308 A3 WO03040308 A3 WO 03040308A3
Authority
WO
WIPO (PCT)
Prior art keywords
odn
sscl
encapsulating
cationic liposomes
sterically stabilized
Prior art date
Application number
PCT/US2002/024235
Other languages
French (fr)
Other versions
WO2003040308A2 (en
Inventor
Dennis M Klinman
Ihsan Gursel
Ken J Ishii
Koji Kawakami
Bharat H Joshi
Raj K Puri
Original Assignee
Us Gov Health & Human Serv
Dennis M Klinman
Ihsan Gursel
Ken J Ishii
Koji Kawakami
Bharat H Joshi
Raj K Puri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Dennis M Klinman, Ihsan Gursel, Ken J Ishii, Koji Kawakami, Bharat H Joshi, Raj K Puri filed Critical Us Gov Health & Human Serv
Priority to US10/484,991 priority Critical patent/US7666674B2/en
Publication of WO2003040308A2 publication Critical patent/WO2003040308A2/en
Publication of WO2003040308A3 publication Critical patent/WO2003040308A3/en
Priority to US12/647,320 priority patent/US20100104507A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapsulating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
PCT/US2002/024235 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo WO2003040308A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/484,991 US7666674B2 (en) 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US12/647,320 US20100104507A1 (en) 2001-07-27 2009-12-24 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30828301P 2001-07-27 2001-07-27
US60/308,283 2001-07-27
US20640702A 2002-07-25 2002-07-25
US10/206,407 2002-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US20640702A Continuation-In-Part 2001-07-27 2002-07-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/647,320 Continuation US20100104507A1 (en) 2001-07-27 2009-12-24 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Publications (2)

Publication Number Publication Date
WO2003040308A2 WO2003040308A2 (en) 2003-05-15
WO2003040308A3 true WO2003040308A3 (en) 2003-11-20

Family

ID=26901314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024235 WO2003040308A2 (en) 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Country Status (1)

Country Link
WO (1) WO2003040308A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4976653B2 (en) * 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9394369B2 (en) * 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
WO2012142669A1 (en) 2011-04-20 2012-10-26 The University Of Sydney A method for the treatment of a solid tumour
KR101465365B1 (en) * 2013-10-15 2014-11-25 성균관대학교산학협력단 Lipid-supported polymeric functional particles and method thereof
WO2017048860A1 (en) * 2015-09-14 2017-03-23 Vgsk Technologies, Inc. A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal
EP3824891A4 (en) * 2018-07-19 2022-07-13 The Research Foundation for Microbial Diseases of Osaka University Lipid particle containing a-type cpg oligodeoxynucleotide
CN110772635B (en) * 2019-11-11 2023-01-31 扬州大学 Bionic nano vaccine coated by influenza virus corpuscle and preparation method thereof
CN113975408A (en) * 2021-08-26 2022-01-28 上海市肿瘤研究所 Nano vaccine based on non-methylated CpG, preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEI ET AL.: "The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice", JOURNAL OF IMMUNOTHERAPY, vol. 21, no. 3, 1998, pages 159 - 169, XP002963675 *
FRIEDMARK ET AL.: "Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes", THE JOURNAL OF IMMUNOLOGY, vol. 160, 1998, pages 4580 - 4586, XP002067073 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Also Published As

Publication number Publication date
WO2003040308A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003040308A3 (en) Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
ES2551233T3 (en) Methods for the preparation of cytotoxic conjugates of maitansinoids and agents that bind to cells
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB0025577D0 (en) Vaccine
CA2413629A1 (en) Solid method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
WO2003068144A3 (en) Cytotoxic agents
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2006085973A3 (en) Antisense antibacterial method and compound
WO2002000194A3 (en) Polymeric micelle compositions
AU2001251637A1 (en) E-coupon channel and method for delivery of e-coupons to wireless devices
WO2002038105A3 (en) Novel polyamine analog-amino acid conjugates useful as anticancer agents
AU2001240753A1 (en) Lipid nanocapsules, preparation method and use as medicine
EP1146855A4 (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
ATE245662T1 (en) AVIDIN-BIOTIN IMMUNOCONJUGATES
WO2002009754A1 (en) Novel remedies for cancer
WO2002022169A3 (en) VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
WO2003045965A3 (en) Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
PT1339862E (en) Photochemical internalization for virus-mediated molecule delivery into the cytosol
WO2001052874A3 (en) Intra-tumoral administration of il-12 encoding nucleic acid molecules
HUP0500180A3 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
WO1999055855A3 (en) Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
CA2356959A1 (en) Water-insoluble drug delivery system
WO1998017814A3 (en) Gene expression and delivery systems and uses
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
HUP0302310A3 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10484991

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP